Meeting
2024 ASCO Genitourinary Cancers Symposium
PIVOT-006: A phase 3, randomized study of cretostimogene grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT).
Authors
Robert S. Svatek
UT Health San Antonio, San Antonio, TX
Robert S. Svatek , Trinity Bivalacqua , Kirk A. Keegan , Siamak Daneshmand
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
Pending
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS715)
DOI
10.1200/JCO.2024.42.4_suppl.TPS715
Abstract #
TPS715
Poster Bd #
M15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore
Poster
2023 ASCO Genitourinary Cancers Symposium
Randomized phase III clinical trial of neoadjuvant intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve non-muscle invasive bladder cancer (NMIBC).
First Author: Massimo Lazzeri
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
First Author: Edward M. Uchio
Poster
2019 Genitourinary Cancers Symposium
A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
First Author: Victoria K Woodcock